Products - Colorectal cancer | Topic | NICE

Showing 52 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter
Guidance programme: Diagnostics guidanceRemove ‘Guidance programme: Diagnostics guidance’ filter
Guidance programme: Interventional procedures guidanceRemove ‘Guidance programme: Interventional procedures guidance’ filter
Guidance programme: Medical technologies guidanceRemove ‘Guidance programme: Medical technologies guidance’ filter

Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (TA1008)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 September 2024
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (TA914)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 September 2023
Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care (DG56)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
24 August 2023
Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancer (IPG763)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
6 June 2023
Regorafenib for previously treated metastatic colorectal cancer (TA866)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 February 2023
Transanal total mesorectal excision for rectal cancer (IPG713)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
15 December 2021
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA716)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 July 2021
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 June 2021
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 January 2021
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 May 2020
Selective internal radiation therapy for unresectable colorectal metastases in the liver (IPG672)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
4 March 2020
Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer (IPG659)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
14 August 2019
Endocuff Vision for assisting visualisation during colonoscopy (MTG45)
Product type:
Guidance
Programme:
Medical technologies guidance
Published:
7 June 2019
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
25 September 2017
Published:
29 March 2017
Endoscopic full thickness removal of non-lifting colonic polyps (IPG580)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
24 May 2017
Virtual chromoendoscopy to assess colorectal polyps during colonoscopy (DG28)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
10 May 2017
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TA240)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
29 March 2017
Published:
14 December 2011
Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
22 February 2017
Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 August 2016
Microwave ablation for treating liver metastases (IPG553)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 April 2016
Low energy contact X-ray brachytherapy (the Papillon technique) for early stage rectal cancer (IPG532)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 September 2015
Preoperative high dose rate brachytherapy for rectal cancer (IPG531)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
26 August 2015
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 February 2015
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
10 December 2014
Combined endoscopic and laparoscopic removal of colonic polyps (IPG503)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
26 September 2014
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 March 2014
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 January 2012
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 January 2012
Published:
24 January 2007
Endoscopic radical inguinal lymphadenectomy (IPG398)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 June 2011
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 December 2010
Radiofrequency ablation for colorectal liver metastases (IPG327)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
16 December 2009
Laparoscopic surgery for colorectal cancer (TA105)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 August 2006
Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer (TA100)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 April 2006
Computed tomographic colonography (virtual colonoscopy) (IPG129)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 June 2005
Complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique) (IPG56)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 April 2004
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 May 2003
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
11 June 2025
Low energy contact X-ray brachytherapy (the Papillon technique) for rectal cancer
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
13 November 2025
Artificial intelligence software to help detect and characterise colorectal polyps
Status:
In development
Programme:
Diagnostics guidance
Expected publication date:
22 January 2026
Colon cancer (adjuvant) - irinotecan [ID379]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selective internal radiation therapy for unresectable colorectal metastases in the liver
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Fruquintinib for previously treated metastatic colorectal cancer ID6274
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
The Extraperitoneal approach to left sided colorectal resections ( EXPERTS) Procedure
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Signatera molecular residual disease assay (MT741)
Status:
Topic selection
Programme:
Medical technologies guidance
Expected publication date:
TBC
Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years [TSID12116]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
High resolution anoscopy and laser therapy for intraepithelial neoplasia of the anus in high risk or immunocompromised patients
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC